Navigation Links
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
Date:2/19/2009

Efficacy and Safety Study in Patients with Severe Post-Operative Pain; Data to Serve as Predictor of Clinical Benefits and Support NDA Submission

SYDNEY and BEDMINSTER, N.J., Feb. 19 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today the initiation of a comparative 3-arm pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients who have undergone total knee replacement surgery. Data from this study will be used to further establish the optimal dose regimen for MoxDuo(TM) IR, select an appropriate control group, and properly design an upcoming pivotal Phase 3 trial in patients following total knee replacement surgery. The company expects to complete dosing in April 2009 and is on track to launch MoxDuo(TM) IR in the US marketplace in 2011. Specifically, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US.

"This study represents an important step forward as the data collected will not only provide critical insights for structuring Phase 3 trials leading to product approval, but also serve as an important indicator of the clinical and commercial value MoxDuo(TM) IR offers," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Doctors are looking for new ways to manage the treatment of severe post-operative pain. We anticipate that QRxPharma's patented MoxDuo(TM) IR will greatly improve patient care by providing equal or better analgesia with fewer and less intense side effects than the current standards of care."

In this clinical trial, each group of patients experiencing moderate to severe postoperative pain following total knee r
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , May 29, 2015 ... the addition of the "2015 Assessments ... Major Suppliers and Recent Market Entrants" ... new 90-page report from VPGMarketResearch.com provides insightful ... recent market entrants. The report ...
(Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
(Date:5/31/2015)... , June 1, 2015 ... rare diseases, has selected Veeva Commercial Cloud to ... and medical. A complete solution, Veeva Commercial ... and compliant content to provide a comprehensive view ... execution.      (Logo: http://photos.prnewswire.com/prnh/20120425/527164) , ...
(Date:5/31/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... and drug-delivery therapies, today announced interim findings from ... investigational new drug PEGPH20 for the potential treatment ... The encouraging interim data was presented today at ... in an oral presentation by Principal Investigator ...
Breaking Biology Technology:Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... system, described as a breakthrough advancement in breast imaging, ... Drug Administration. , ,The system offers more evidence that ... tools that enable higher quality images for the detection ... GE Healthcare said the Senographe Essential system ...
... we asked William Yasnoff, founder of the eHealthTrust initiative, why ... that today are fractured and limited. , , ... William Yasnoff Yasnoff is a speaker at ... deliver a presentation titled "A New Patient-Centric and Sustainable Approach ...
... Madison, Wis. The Wisconsin Technology Council ... legislature with statewide membership arms, has announced eight additions ... have three-year terms and will join a board that ... business technology community. Electees include four technology organization leaders: ...
Cached Biology Technology:FDA approves advanced digital mammography system 2Interview: Dr. William Yasnoff on health records, part 2 2Interview: Dr. William Yasnoff on health records, part 2 3Interview: Dr. William Yasnoff on health records, part 2 4Interview: Dr. William Yasnoff on health records, part 2 5Interview: Dr. William Yasnoff on health records, part 2 6
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... free. But we'd all agree it's not worthless. So, ... , In 1997, the University of Vermont's Robert Costanza ... per year in a now-famous paper in the journal ... services" has bloomed. This young discipline studies how nature--through ...
... developed the first-ever genomic test to predict which patients ... and which patients can avoid the toxic regimen of ... save thousands of lives each year by recommending chemotherapy ... the test's developers at Duke's Institute for Genome Sciences ...
... therapy extends average life expectancy and decreases recurrences of ... lung cancer, according to researchers at Rhode Island Hospital. ... seven years, the median survival rate at three years ... months when thermal ablation was followed by radiation for ...
Cached Biology News:What's nature worth? New computer models tell all 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
... Most sensitive silver stain. ... stop baths or reversers needed. ... and polysaccharides. Linear protein-to-stain ... stain multiple gels per tray. ...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Biology Products: